UNSPSC 51313205: Levocabastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H29FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H68BP06S81, chemically known as 4-piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, (3s-(1(cis),3alpha,4beta))- but generally known as levocabastine, which bears US NIH Compound Identifier 54385. European Medicines Agency schedules Levocabastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08465MIG.

UNSPSC 51313205 Levocabastine is a Commodity code that nominally identifies a specific antihistamine medication, but recent state and local procurement activity under this code shows little alignment with the code's pharmaceutical specificity. The opportunities posted show state and local government procurement of naloxone, safe drug deactivation systems, and broader generic pharmaceutical and over-the-counter product portfolios — categories that diverge materially from levocabastine's narrow therapeutic classification. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). These entities are sourcing pharmaceutical products and medical countermeasures through a mix of direct procurement and cooperative purchasing vehicles, with requirements for FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and substantial insurance coverage.

Recent activity concentrates in Florida and Texas, with cooperative purchasing extending across the Upper Midwest and Pacific Northwest through MMCAP membership. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor market intelligence on direct-to-manufacturer prescription programs for self-insured health plans, a preliminary information-gathering phase preceding formal competitive solicitation. The Minnesota Multistate Cooperative Purchasing Alliance released RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and the remainder on fixed pricing, cGMP compliance, EDI capability, and administrative fee acceptance. The code shows material recent activity but appears misaligned with levocabastine's nominal scope.